You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
環亞國際醫療集團(01143.HK)擬組建合資 開展子宮內膜幹細胞存儲和生育健康管理業務
格隆匯 03-18 22:31

格隆匯 3 月 18日丨環亞國際醫療集團(01143.HK)公吿,於2021年3月18日收市後,公司透過全資子公司,環亞國際細胞科技集團有限公司("環亞細胞科技"),漢光雲科(上海)生物醫藥科技有限公司("漢光雲科")訂立合資合作備忘錄。環亞細胞科技及漢光雲科同意組建合資公司擬開展子宮內膜幹細胞存儲和生育健康管理業務。

根據備忘錄,於合資公司成立後,環亞細胞科技擬持有合資公司多數控股權。同時,擬聘請王學軍出任合資公司管理層,負責合資公司的日常運營及管理。

自備忘錄簽訂日期起計60日內,環亞細胞科技將對漢光雲科進行盡職調查。待盡職調查完成且環亞細胞科技認為滿意後,環亞細胞科技將與漢光雲科簽署正式的投資合作協議,約定合資公司投資的細節。

集團主要從事(i)電子製造服務;(ii)行銷及分銷通訊產品;(iii)房地產供應鏈服務;及(iv)證券及其他資產投資。

鑑於新型冠狀病毒病對全球經濟帶來的挑戰,董事會和公司管理層目前不僅致力於發展集團現有的核心業務,仍正在積極探索新業務,尤其是市場需求龐大的輔助生殖醫療科技業務。根據相關研究表明,女性宮內膜幹細胞可被廣泛用於各種婦科疾病的治療,包括卵巢早衰、子宮腔粘連、子宮內膜異位症、不孕症、子宮內膜增生、宮內膜癌等,臨牀應用前景廣闊。宮內膜幹細胞的存儲管理,為治療不孕不育類疾病提供重要保障,助力輔助生殖業務的發展。

董事會認為通過(i)與戰略合作方設立合資公司;(ii)引入在生物技術開發與應用方面具有卓越才能及豐富經驗的管理團隊;及(iii)依託科技創新,可以不斷夯實集團在輔助生殖科技、細胞科技領域的產業鏈佈局,如果交易實現,將有助於集團將其現有業務重組為具有增長潛力的行業。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account